C5
60 programs · 58 companies
Programs
60
Companies
58
Active Trials
43
Targeting C5
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | PAHWM | |
| LLY-1184 | Eli Lilly | NDA/BLA | PVCSU | |
| RHH-1546 | Roche | Phase 2/3 | WMIPF | |
| BAY-6035 | Bayer | Phase 1 | SLE | |
| ARG-1250 | Argenx | Phase 2 | Ewing Sarcoma | |
| Elratapinarof | Halozyme | Phase 2 | ET | |
| HAL-1232 | Halozyme | Approved | Breast Ca | |
| XEN-577 | Xenon Pharma | Phase 2/3 | Myelofibrosis | |
| Olpasotorasib | Structure Ther | Preclinical | SCLCSLE | |
| Zoriosocimab | Akero | Approved | MCCNB | |
| Rimainavolisib | Apogee Ther | Phase 2 | Endometrial Ca | |
| Doxacagene | Verve | Phase 1/2 | Pancreatic CaMigraine | |
| PRM-116 | Prime Medicine | NDA/BLA | EoE | |
| NMR-223 | Neumora | NDA/BLA | PsoriasisBCC | |
| Mavucagene | 10x Genomics | Preclinical | Ewing SarcomaPsoriasis | |
| Semaosocimab | Eisai | Phase 1 | T2D | |
| Pexaosocimab | Ipsen | Phase 2/3 | RCC | |
| HCM-2035 | Hutchmed | Preclinical | HS | |
| SWO-IIT-993 | SWOG | Approved | CF | |
| JOH-IIT-536 | Johns Hopkins | Phase 2 | NASH | |
| DUK-IIT-841 | Duke Cancer Institute | Phase 1 | ADPKD | |
| AVB-7847 | ArriVent BioPharma | Phase 1/2 | IPFLGS | |
| Tixaglumide | Compass Ther | Preclinical | Pancreatic CaNASH | |
| Miricilimab | Septerna | Phase 2 | NBNarcolepsy | |
| Talavorutinib | Abivax | Phase 1 | Parkinson's | |
| NKT-344 | Nkarta | Phase 1 | BCCGA | |
| Datorasimod | NovaBay Pharma | Approved | GBMParkinson's | |
| TUR-4034 | Turning Point (BMS) | Phase 2/3 | Psoriasis | |
| GAL-555 | Galena Biopharma | Phase 3 | UCPsoriasis | |
| Polatuximab | BioAtla | Phase 1 | Ewing Sarcoma | |
| AVE-4742 | Aveo Pharma (LG Chem) | Phase 1 | PsAMeso | |
| BTA-3746 | Bioxcel Therapeutics | Phase 2 | MyelofibrosisBCC | |
| Terarapivir | Acer Therapeutics | Phase 1 | RB | |
| Capitinib | Shanghai Pharma | Phase 1 | AsthmaCeliac | |
| Fixabrutinib | I-Mab | Preclinical | Bladder Ca | |
| Lisonesiran | Sorrento Ther | NDA/BLA | DLBCLAsthma | |
| ORC-9172 | Orchard (Kyowa) | Phase 3 | OCD | |
| TUR-4491 | Turnstone Bio | NDA/BLA | Crohn'sMDD | |
| 451-4283 | Nippon Shinyaku | Phase 2 | ADHDHCC | |
| 069-1659 | Daewoong Pharma | Preclinical | Atopic DermMDD | |
| 199-2212 | ToolGen | Phase 2/3 | UCNB | |
| ACH-7772 | Achilles (BMS) | Phase 1 | ETEwing Sarcoma | |
| Gelisacituzumab | Genkyotex (Calliditas) | Phase 2 | RSV | |
| Rimasacituzumab | Merck KGaA | Phase 3 | CFCLL | |
| ALM-7482 | Almirall | Approved | EoESCLC | |
| Datofotisoran | Clarity Pharma | Phase 1/2 | Urothelial CaDMD | |
| URG-1959 | UroGen | Phase 3 | BCC | |
| Suranaritide | Tolmar | Phase 1/2 | SMATTR Amyloidosis | |
| RLF-5973 | Relief Therapeutics | Phase 3 | Breast Ca | |
| Nidaglumide | Stallergenes Greer | Approved | MCCIgAN | |
| Motaderotide | HLB Inc | Phase 2 | PAHMDS | |
| Tezesacituzumab | Procaps Group | Phase 2 | EoEAML | |
| Ribozasiran | Neopharma | Phase 1/2 | EpilepsyEoE | |
| RIK-IIT-658 | RIKEN | Phase 3 | FL | |
| Nidaratamab | Scientus Pharma | Approved | RAPsA | |
| Teraosocimab | Avantor | Approved | NBMS | |
| Nidarelsin | Oragenics | Phase 2/3 | AsthmaMCL | |
| Bemazanubrutinib | Certara | Preclinical | CLLCrohn's | |
| Polanaritide | PathAI | Phase 1/2 | MGMCC | |
| Mavuvorutinib | Abbisko Therapeutics | Phase 2/3 | GIST |